TY - JOUR
T1 - The Medical Necessity of Comprehensive Patch Testing
AU - Zhu, Tian Hao
AU - Suresh, Raagini
AU - Warshaw, Erin
AU - Scheinman, Pamela
AU - Mowad, Christen
AU - Botto, Nina
AU - Brod, Bruce
AU - Taylor, James S.
AU - Atwater, Amber Reck
AU - Watsky, Kalman
AU - Schalock, Peter C.
AU - MacHler, Brian C.
AU - Helms, Stephen
AU - Jacob, Sharon E.
AU - Murase, Jenny E.
N1 - Publisher Copyright:
© 2018 American Contact Dermatitis Society. All Rights Reserved.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Allergic contact dermatitis is associated with significant disease and economic burden in the United States. To properly manage allergic contact dermatitis, it is important to accurately identify the substance(s) implicated in the dermatitis to prevent disease recurrence. The commercially available T.R.U.E Test (36 allergens) screening panel has been reported to have a conservative hypothetical allergen detection rate of 66.0%, at most. Importantly, these calculations are based on the 78% of patients who had clinically relevant reactions to allergens present on the North American Contact Dermatitis Group screening series (70 allergens), without the use of supplemental allergens. Testing with supplemental allergens beyond a screening series can more fully evaluate an individual's environmental and occupational exposure, which may significantly increase diagnostic accuracy. Comprehensive patch testing with additional allergens in sunscreens, cosmetics, and fragrances, for example, may increase the diagnostic yield as well as the likelihood of achieving a cure if the dermatitis is chronic and recalcitrant.
AB - Allergic contact dermatitis is associated with significant disease and economic burden in the United States. To properly manage allergic contact dermatitis, it is important to accurately identify the substance(s) implicated in the dermatitis to prevent disease recurrence. The commercially available T.R.U.E Test (36 allergens) screening panel has been reported to have a conservative hypothetical allergen detection rate of 66.0%, at most. Importantly, these calculations are based on the 78% of patients who had clinically relevant reactions to allergens present on the North American Contact Dermatitis Group screening series (70 allergens), without the use of supplemental allergens. Testing with supplemental allergens beyond a screening series can more fully evaluate an individual's environmental and occupational exposure, which may significantly increase diagnostic accuracy. Comprehensive patch testing with additional allergens in sunscreens, cosmetics, and fragrances, for example, may increase the diagnostic yield as well as the likelihood of achieving a cure if the dermatitis is chronic and recalcitrant.
UR - http://www.scopus.com/inward/record.url?scp=85047216626&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047216626&partnerID=8YFLogxK
U2 - 10.1097/DER.0000000000000362
DO - 10.1097/DER.0000000000000362
M3 - Review article
C2 - 29613858
SN - 1710-3568
VL - 29
SP - 107
EP - 111
JO - Dermatitis
JF - Dermatitis
IS - 3
ER -